𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏

⭐️What to look 👀 for in your urine for cancer? Honored to film this public announcement for cancer awareness @BladderCancerUS @WorldBladderCan @IBCG_BladderCA @AmericanCancer #PatientCare #Healthcare #CancerAwareness #KnowledgeCanDiminishFear

Join @CParkMD & me on Dec 13 in Seattle for a fantastic Master Lectures series with stellar speakers, interactions, fun! Register below: masterlectureseries.com/registration-m… @PavlosMsaouel @mshadman @RahulBanerjeeMD @DRBakaloudiMD @DMakrakisMD @HsiehLab @DimaDanai @fredhutch @DrOmarMian

Updated results from KEYNOTE-B61: First-line pembrolizumab + lenvatinib in advanced non-clear-cell RCC shows: ✅ ORR 51% ✅ CR in 8.2% ✅ Median DOR 19.5 mo A promising option for nccRCC. #oncology #kidneycancer @EUplatinum @AlbigesL @OncoAlert @Uromigos pubmed.ncbi.nlm.nih.gov/40707309/

🚨 FDA grants Priority Review to Johnson & Johnson’s TAR-200, a novel intravesical gemcitabine delivery system for BCG-unresponsive high-risk NMIBC (CIS ± papillary tumors). 📊 In SunRISe-1, TAR-200 showed 82.4% CR and >50% cancer-free at 1 year. #BladderCancer #Immunotherapy…

Magnitude of OS benefit for FLAURA2 will be relevant here. Since crossover was not mandated per study design, the next question should be what did the control arm receive and when? IMO - the central clinical, real world, question that FLAURA2 is trying to answer is whether…

Received a Texas sized farewell from my @MDAndersonNews family, complete with an exceptional brisket from top chef @eugenekoay. Thanks to Stacy & Eugene for hosting and the gang for 12 AMAZING years of friendship & collaboration (both keep going!) Grateful to all of you 🙏🏽🙏🏽

🚨 Big news in #lungcancer! 📢 Final OS data from FLAURA2 💊 Tagrisso + chemo ⬆️ overall survival in 1L EGFRm NSCLC vs Tagrisso alone 🔑 Statistically & clinically meaningful 🧬 Longest median PFS in class 🛡 No restriction on post-progression Rx . It will be intresting to see…

our #lungcancer session at MECC New Orleans 2025 with @drgandara @IASLC Karen Kelly @lungoncdoc @JuliaRotow Paul Bunn Subramanian @fred_hirsch @EdgardoSantosMD Megan Daly Erminia Mazarelli #lcsm @mecmededucation

That feeling when 7+ years of work lands on the front page of @NEJM—and one of the people I respect most, @KoheiShitara , writes the editorial. Honored to share this moment with you, Kohei. Here’s to a decade of friendship, and curing gastric cancer. #Matterhorn @MSKCancerCenter

In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surgery-based approaches. However, post-metastasis survival does not differ between treatments. @EurUrolOncol @DrSpratticus @OncoAlert @APCCC_Lugano @Uroweb…

Fantastic to interview my colleague Dr. John Gore @uwurology @fredhutch on CISTO study that he presented @AmerUrological patient centered & pragmatic study helped answer key questions with interesting results! @spsutkaMD @CParkMD @oncodaily @DanLinMD youtu.be/s4IJA1KaoUI

One of the reasons I love @kidneycan's #KCRS25: Hearing luminaries in the field of #kidneycancer present their take on data hot off the press. So cool to see @DrChoueiri @motzermd @NaomiHaas5 #McDermott sharing a stage & offering perspective on the latest from @ASCO, @myESMO &…

At NOSCM, @JuliaRotow presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled

Kick-off call for my ⁦@ASCO⁩ Virtual Mentorship Program #VMP 2025-26 class | it will be a fun journey with 5 mentees 🇹🇷🇲🇽🇺🇸 ⁦@imdat_eroglu⁩ ⁦@Rf_Correa⁩ ⁦@jordanciuro⁩ #SuleymanKarakeçi #HalilİbrahimEllez | ⁦@BrigidaMaiorano⁩ dropbox.com/scl/fi/mkfssgr…

🚨 MET in Cancer: Mutation, Amplification & Resistance 🧬 MET is a key oncogenic driver—especially in NSCLC, HCC, gastric & RCC. But resistance is smart. It strikes via: 1️⃣ On-target MET mutations (e.g., D1228N, Y1230C/S/H) 2️⃣ Downstream rewiring (KRAS, BRAF, PI3K, PTEN, MYC) 3️⃣…

🌟 @KimrynRathmell shares her story and inspires action to fight brain drain 🧠💨: empower early careers 🚀, mentor to create opportunity 🤝, and ensure institutions 🏛️ bring young voices to the table while valuing mentors fully 🌱✨ @kidneycan #kcrs25

💡 Great review of progress over the last 10 years in 1st-line metastatic RCC 🚀 and a call from David McDermott to work together to cure more patients with kidney cancer 🤝 @kidneycan #KCRS25 #rcc #kidneycancer

It feels truly surreal to be entering this hematology-oncology fellowship application cycle, pursuing my passion for GIOncology. My interests focus on GI cancers, early-onset malignancies, and healthcare disparities, with a special focus on clinical trials. Grateful to all my…

Celebrating the winners of the KCRS25 Merit Awards for Clinical Research! 👏 Dr. Yu-wei Chen, University of California San Diego 👏 Dr. Koral Shah, City of Hope 👏 Ruchi Agarwal, University of Pennsylvania #KCRS25 #AcceleratingCures

At the heart of science. Not just the data, but how it reaches patients, this is what truly matters. Great discussion on global disparities. Congrats @ruchia_upenn @montypal #KCRS25 #KidneyCancer @OncoAlert @kidneycan @urotoday @cityofhope @neerajaiims

A force of nature, a catalyst for change and an incomparable energy ! Congrats @DrRanaMcKay @UCSDCancer ! @kidneycan #KCRS2025